Skip to content
MARKETS / NASDAQ / SKIN
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

SkinHealth Systems Inc. SKIN

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$300.8M
▼ 10.0% YoY
$-9.5M
$37.2M
▲ 141.8% YoY
In brief

What this company does

The Company sells Delivery Systems, devices that providers use to perform its treatments, along with single-use Consumables such as tips, solutions and serums that can be purchased separately or together with the devices. The majority of its customers are providers within the professional medical industry, including dermatologists, plastic surgeons and medical spas, along with estheticians and beauty retailers such as spas and hotels, and it currently sells approximately 69% of its Delivery Systems and Consumables into the professional medical channel in the United States and Canada. Its Delivery Systems are manufactured and assembled at a manufacturing facility in Long Beach, California, while manufacturing of other products is outsourced to contract manufacturers located primarily in North America, Europe and Asia. In 2025, total net sales from markets outside the United States and Canada comprised approximately 35% of total net sales. Its offerings are organized around the Hydrafacial treatment together with SkinStylus microneedling and HydraScalp powered by Keravive.

Written from the business description in The Beauty Health Company's annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.

Growth
USD 300.8M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 300.8 · Net income -9.5
200M-200M2019202020212022202320242025
Compound annual growth
−6.3%
+20.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +20.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−3 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6.9% · Net -3.2%
-50%-100%2019202020212022202320242025
ROE
FY2025 · ROE -16.9%
-100%-200%2019202020212022202320242025

Each USD of equity lost 17 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 37.2
20M-40M-80M2019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 0.0
80M2019202020212022202320242025

Total assetsUSD 499.8M
EquityUSD 61.1M
CashUSD 232.7M
Current ratio1.66×

Equity funds 12% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.30.30.40.40.30.10.2
Operating income $B−0.0−0.1−0.1−0.0−0.0−0.00.0
EBITDA $B−0.0−0.1−0.1−0.0−0.0−0.00.0
Income tax $B0.0−0.0−0.00.0−0.0−0.0−0.0
Net income $B−0.0−0.0−0.10.0−0.4−0.0−0.0
Free cash flow $B0.00.00.0−0.1−0.0−0.0−0.0
EPS, diluted $−0.16−0.36−0.76−0.23−3.71−0.85−0.05
Dividend / sh $·······
Payout %·······
ROE %−16.9−52.3−88.419.0−283.2··
Shares out B0.130.120.120.130.130.040.03

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image